交易信息汇总资金流向 截至2025年11月17日收盘，华北制药(600812)报收于6.15元，下跌1.28%，换手率1.13%，成交量19.34万 手，成交额1.19亿元。 当日关注点 华北制药股份有限公司于2025年5月16日发行2025年度第一期短期融资券，发行总额为人民币5.00亿 元，发行利率1.86%，期限180日，兑付日期为2025年11月15日。截至2025年11月17日，公司已完成本 期短期融资券的兑付工作，本息兑付金额共计人民币504,586,301.37元。 11月17日主力资金净流出590.71万元，占总成交额4.96%；游资资金净流入178.46万元，占总成交额 1.5%；散户资金净流入412.25万元，占总成交额3.46%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：11月17日主力资金净流出590.71万元，占总成交额4.96%。 来自公司公告汇总：华北制药已于2025年11月17日完成2025年度第一期短期融资券本息兑付，合 计支付504,586,301.37元。 公司公告汇总 ...

华北制药股份有限公司（以下简称"公司"）于2025年5月16日成功发 行华北制药股份有限公司2025年度第一期短期融资券（以下简称"本期短 期融资券"），本期短期融资券发行总额为人民币5.00亿元，发行利率1.86%， 期限为180日，兑付日期为2025年11月15日（若遇节假日顺延）。具体内容 详见公司于2025年5月20日登载于上海证券交易所网站（www.sse.com.cn） 的《2025年度第一期短期融资券发行结果的公告》（公告编号：2025-026 号）。 2025 年度第一期短期融资券兑付完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至2025年11月17日，公司已完成本期短期融资券的兑付工作，本息 兑付金额共计人民币504,586,301.37元。 特此公告。 证券代码：600812 股票简称：华北制药 编号：临 2025-056 华北制药股份有限公司 华北制药股份有限公司 2025 年 11 月 17 日 ...

Core Viewpoint - North China Pharmaceutical announced the approval of its subsidiary Hebei Huamin Pharmaceutical's application for the marketing of the chemical raw material drug Cefotolan Pivoxil by the National Medical Products Administration [2] Group 1 - The approval notification for Cefotolan Pivoxil marks a significant milestone for the company [2] - The drug is expected to enhance the company's product portfolio and market competitiveness [2] - This development reflects the company's ongoing commitment to expanding its pharmaceutical offerings [2]

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]

Core Viewpoint - Huabei Pharmaceutical's subsidiary, Hebei Huamin Pharmaceutical Co., has received approval from the National Medical Products Administration for the marketing application of Cefotolan Pivoxil, a third-generation cephalosporin antibiotic [1] Group 1: Product Details - Cefotolan Pivoxil is a third-generation cephalosporin antibiotic that is hydrolyzed into the active form Cefotolan after absorption, exhibiting antibacterial properties [1] - The antibiotic shows significant effectiveness against five major pathogens causing community-acquired respiratory infections, particularly against penicillin-resistant Streptococcus pneumoniae and Staphylococcus aureus [1] Group 2: Indications - The product is indicated for infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and secondary infections from trauma, burns, and surgical wounds [1] - Additional indications include perianal abscess, pharyngitis, laryngitis, tonsillitis (including peritonsillar abscess), acute bronchitis, pneumonia, lung abscess, chronic respiratory infections, otitis media, sinusitis, periodontitis, jaw inflammation, cystitis, pyelonephritis, scarlet fever, and whooping cough [1]

Core Viewpoint - Company Huabei Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Cefotolan Pivoxil, a third-generation cephalosporin antibiotic [1] Group 1: Product Approval - Huabei Pharmaceutical's wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., has been granted the marketing approval for Cefotolan Pivoxil [1] - Cefotolan Pivoxil is a third-generation cephalosporin antibiotic that is hydrolyzed into the active form Cefotolan after absorption [1] Group 2: Antibacterial Efficacy - Cefotolan Pivoxil shows significant effectiveness against five major pathogens causing community-acquired respiratory infections, particularly against penicillin-resistant Streptococcus pneumoniae and Staphylococcus aureus [1] - The drug is suitable for treating infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and various respiratory infections [1]

证券代码：600812 股票简称：华北制药 编号：临 2025-055 | 通用名称：头孢托仑匹酯 | | 化学原料药名称 | | --- | --- | --- | | 英文名/拉丁名：Cefditoren | Pivoxil | | | CYHS2460452 | | 受理号 | | 2025YS00962 | | 通知书编号 | | 境内生产化学原料药上市申请 | | 申请事项 | | YBY71282025 | | 化学原料药注册标准 编号 | | 个月 | 18 | 有效期 | | 25Kg/袋 | | 包装规格 | | 名称：华北制药河北华民药业有限责任公司 | 地址：石家庄经济技术开发区海南路 98 号 | 生产企业 | | Y20240000528 | | 登记号 | | 至 | 年 月 日 2030 11 2 | 通知书有效期 | | 根据《中华人民共和国药品管理法》及有关规定，经审查，本品 | 符合药品注册的有关要求，批准注册。 | 审批结论 | 二、药品其他相关情况 头孢托仑匹酯属于第三代头孢菌素抗生素，属于头孢托仑的特戊酰氧 甲酯，吸收后被水解为活性体头孢托仑而发挥抗菌作用，与其他第三 ...

Core Viewpoint - Company Huabei Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Cefotolan Pivoxil, a third-generation cephalosporin antibiotic [1] Group 1: Product Information - Cefotolan Pivoxil is a third-generation cephalosporin antibiotic that is hydrolyzed into its active form, Cefotolan, after absorption, providing antibacterial effects [1] - The antibiotic shows significant efficacy against five major pathogens causing community-acquired respiratory infections, particularly against penicillin-resistant Streptococcus pneumoniae and Staphylococcus aureus [1] - The product is indicated for various infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and respiratory tract infections [1]

Market Overview - The Shanghai Composite Index closed at 3976.52 points, above the annual line, with a gain of 0.55% [1] - The total trading volume of A-shares reached 21,329.04 million yuan [1] Stocks Breaking Annual Line - A total of 110 A-shares have surpassed the annual line today, with notable stocks including: - Deer Chemical with a deviation rate of 14.65% - Yabao Chemical at 11.35% - Fushi Holdings at 10.87% [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the annual line: - Deer Chemical: 20.75% increase, latest price 16.06 yuan, deviation rate 14.65% [1] - Yabao Chemical: 11.98% increase, latest price 8.13 yuan, deviation rate 11.35% [1] - Fushi Holdings: 13.39% increase, latest price 5.76 yuan, deviation rate 10.87% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Meirui New Materials: 19.99% increase, latest price 18.97 yuan, deviation rate 9.48% [1] - Intercontinental Oil and Gas: 10.13% increase, latest price 2.61 yuan, deviation rate 9.37% [1] - Tianjin Pulin: 10.00% increase, latest price 22.23 yuan, deviation rate 7.84% [1]

Group 1 - The core viewpoint of the article highlights the successful issuance of a three-year technology innovation bond by North China Pharmaceutical Co., Ltd., led by the Shijiazhuang branch of Industrial Bank, with a total issuance scale of 500 million yuan [1] - This bond issuance marks the first technology innovation bond in the pharmaceutical industry of Hebei Province, setting a historical low for the interest rate of similar products in the region [1] - The funds raised will provide strong financial support for the company's key technological innovation areas, accelerating the transformation and implementation of innovative results [1] Group 2 - As of September 2025, the Shijiazhuang branch of Industrial Bank has provided over 20 billion yuan in financing support to enterprises in Hebei through investment banking services [2] - The branch has served 15 technology-based enterprises through various services, including non-financial bond underwriting, merger loans, and syndicate loans [2] - The bank plans to deepen its "commercial bank + investment bank" strategy, focusing on the full-cycle needs of technology innovation enterprises and leveraging specialized products like technology innovation bonds to inject stable financial momentum into these companies [2]